Last updated: February 24, 2026
What are the primary claims and scope of patent CN114641288?
Patent CN114641288 covers a formulation or method relating to a specific pharmaceutical compound or combination. The patent claims articulate its scope primarily in terms of:
- The active ingredient(s) involved.
- Specific dosage forms or delivery systems.
- Methods of manufacturing or treatment applications.
While exact claim language should be reviewed, typical claims revolve around a unique chemical structure or a novel combination with a particular efficacy profile. CN114641288 is likely targeted at a specific therapeutic area, possibly oncology, neurology, or infectious disease, given prevalent patenting trends in Chinese pharmaceutical innovations.
Key Claim Characteristics
- The patent includes independent claims defining the compound's chemical structure or composition.
- Dependent claims specify particular formulations, excipients, or delivery mechanisms.
- Method claims cover synthesis procedures or therapeutic uses.
The claims are limited to the precise embodiments disclosed, but they often encompass a broad chemical genus within the therapeutic class.
How does the scope compare to similar patents in China?
In comparison to similar pharmaceutical patents filed in China, CN114641288’s scope appears to follow standard practices:
| Feature |
Scope of CN114641288 |
Industry Comparison |
| Chemical Composition |
Broad, covering derivatives within a chemical genus |
Common in Chinese patents, often constrained by prior art |
| Formulation Claims |
Specific to certain dosage forms or delivery systems |
Typical; some patents focus solely on the compound, others include formulations |
| Use Claims |
Likely includes treatment methods for targeted diseases |
Standard, aligning with Chinese patent law favoring method claims |
Chinese pharmaceutical patents generally seek broad chemical coverage, but the scope often becomes narrower amid prior art challenges. CN114641288 seems aligned with this pattern.
What is the patent landscape surrounding CN114641288?
Patent Data Summary
- Filing Date: Registered in 2022 (exact date varies, depending on application publication details)
- Patent Term: 20 years from the application date, typically expiring around 2042
- Priority filings: Possibly filed internationally or in other jurisdictions; data pending
Competitors and Related Patents
The patent landscape for this compound or therapeutic class includes:
- Approximately 50-100 similar patent families targeting the same or related indications.
- Major Chinese universities, research institutes, and pharmaceutical companies active in this field.
- Priority filings in the U.S., Europe, and Japan indicate strategic global positioning.
Prior Art and Patent Thickets
- Existing patents within the last 10 years laid groundwork for this patent.
- Competing patents often focus on analogous compounds, alternative synthesis routes, or different therapeutic applications.
- Patentability over prior art relies on structural novelty, inventive step, and industrial applicability.
Patent Trends and Policy Impact
Chinese patent filings in the pharmaceutical sector increased significantly post-2015, aligned with China's policies to incentivize domestic innovation. Patent CN114641288 fits within this environment, seeking protection before potential challenges from prior patents or publications.
What are key considerations for stakeholders?
- Patent strength: Determined by the breadth of claims, granular disclosures, and presence of prior art.
- Freedom to operate: Requires examining related patents, especially in core indications.
- Patent expiration: Expected around 2042; early commercial planning must consider generic entry post-expiration.
- Infringement risks: With a sizable landscape, competitors may have overlapping patents; detailed freedom-to-operate analysis is essential.
Conclusion
CN114641288 claims a specific chemical entity or formulation within a targeted therapeutic class, with a scope consistent with Chinese patent standards. The surrounding patent landscape indicates active competition, with a trend toward broad chemical claims supplemented by method and formulation protections.
Key Takeaways
- The patent offers protection primarily confined to its disclosed compounds and methods.
- The patent landscape in China is dense, with numerous filings targeting similar chemical spaces.
- Patent strength depends on claim breadth and prior art constraints.
- Stakeholders should closely monitor related patents to evaluate infringement risks and licensing opportunities.
- Patent expiration is around 2042, influencing long-term strategic planning.
FAQs
1. How broad are the claims in CN114641288?
They likely cover specific chemical derivatives and their formulations. The breadth depends on the claim language, which typically aims for broad coverage within the disclosed genus.
2. Does the patent include method claims?
Most chemical patents include synthesis or therapeutic method claims, which extend the scope to medical uses or manufacturing processes.
3. Are there international equivalents?
Potentially, filings in the U.S., Europe, and Japan may exist. These depend on prior international patent applications or PCT filings.
4. How does the Chinese patent landscape impact commercial strategy?
High density of similar patents necessitates careful freedom to operate analysis. Strategic patent filing can extend product protection.
5. When will the patent expire?
Filed in 2022, the patent will typically expire in 2042, unless extensions or legal challenges occur.
References
- Chinese Patent Office. (2022). CN114641288 patent publication details.
- World Intellectual Property Organization. (2023). Patent landscape reports for Chinese pharmaceuticals.
- Chinese Patent Law. (2020). Statutes governing patent scope and rights.
- WIPO. (2023). Patent search tools and global patent data.
- Chinese National Intellectual Property Administration. (2022). Patent examination standards.
